🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Australia / NCT04253301
Recruiting Not applicable

Feasibility of the InnoVein Valve and Delivery System for Chronic Venous Insufficiency

NCT04253301 · tracked via the Priya Life Science Australia tracker
Sponsor
InnoVein
Phase
Not applicable
Started
2020-01-15
Last updated
2021-09-17

Condition(s) studied

Chronic Venous Insufficiency

Investigational drug(s) / intervention(s)

InnoVein Valve Treatment

InnoVein Valve Treatment: Subjects will have the InnoVein Valve implanted

Study summary

This objective of this feasibility study is to evaluate the safety of the InnoVein Valve and Delivery System for treatment of chronic venous insufficiency.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Willing and able to provide written Informed Consent * Diagnosis of symptomatic non-obstructive chronic valvular insufficiency of the femoral vein * Willing and medically able to receive intraprocedural and post-procedural anticoagulation medication * Life expectancy \>1yr * Reflux time \>1s in the superficial femoral and/or popliteal vein Key Exclusion Criteria: * Any prior deep vein intervention within 6 months prior to the Index Procedure * History of 2+ DVTs * Inadequate inflow to the femoral vein or inadequate outflow through the femoral vein, iliac vein, or IVC * Current IVC Placement * History of pulmonary embolism within 6 months * Conditions that increase the risk of device thrombosis or patient bleeding * Any planned surgical or interventional procedure within 30 days prior to or after the Index Procedure * Investigator or sponsor believes the subject would not benefit, would not be appropriate, be unable to follow-up, or be at high risk for non-compliance with the protocol

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Hollywood Private Hospital Nedlands Western Australia Recruiting
Sir Charles Gairdner Hospital Nedlands Western Australia Recruiting
Flinders Adelaide Australia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04253301 on ClinicalTrials.gov ↗ ← All trials in Australia